SCHEMBL10156256

SCHEMBL10156256

Cc1cncc(-c2ccc3nccc(-c4ccncc4)c3c2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 13/20 0.67
AKT1 P31749 3/20 0.58
MTOR P42345 3/20 0.46
PIK3CG P48736 3/20 0.46
PIK3CD O00329 2/20 0.46
PIK3CB P42338 2/20 0.46
PIK3C3 Q8NEB9 1/20 0.46
MAPK10 P53779 1/20 0.44
MAP4K4 O95819 1/20 0.41
GAK O14976 1/20 0.41
RPS6KA4 O75676 1/20 0.41
STK10 O94804 1/20 0.41
PIM1 P11309 1/20 0.41
CSNK2A2 P19784 1/20 0.41
MAP2K2 P36507 1/20 0.41
CSNK1D P48730 1/20 0.41
CLK1 P49759 1/20 0.41
CLK2 P49760 1/20 0.41
CSNK1G2 P78368 1/20 0.41
MAP2K1 Q02750 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL730195 0.85 PIK3CA (0.84) PIK3CAAKT1MTORPIK3CGPIK3CD
SCHEMBL730188 0.83 PIK3CA (0.87) PIK3CAAKT1MTORPIK3CGPIK3CD
SCHEMBL731482 0.83 PIK3CA (0.67) PIK3CAAKT1MTORPIK3CGPIK3CD
SCHEMBL4755130 0.83 PIK3CA (0.67) PIK3CAAKT1MTORPIK3CGPIK3CD
SCHEMBL731607 0.83 PIK3CA (0.62) PIK3CAAKT1MTORPIK3CGPIK3CD
SCHEMBL729839 0.83 PIK3CA (0.62) PIK3CAAKT1MTORPIK3CGPIK3CD
SCHEMBL729836 0.82 PIK3CA (0.74) PIK3CAAKT1MTORPIK3CGPIK3CD
SCHEMBL3649670 0.81 PIK3CA (0.60) PIK3CAAKT1MTORPIK3CGPIK3CD
SCHEMBL729739 0.81 PIK3CA (0.63) PIK3CAAKT1MTORPIK3CGPIK3CD
SCHEMBL732085 0.80 PIK3CA (0.62) PIK3CAAKT1MTORPIK3CGPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140296224-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2014-10-02 US disclosed
US-8785433-B2 Quinoline derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-22 US disclosed
US-8633187-B2 Quinoline derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2014-01-21 US disclosed
US-20120165321-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165321-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS PIK3CD, PIK3CG, PIK3CB PIK3CA 6/4885AKT1 66/4885MTOR 59/4885
US-20140296224-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS PIK3CD, PIK3CG, PIK3CB PIK3CA 6/4885AKT1 66/4885MTOR 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.